Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Targeted Therapy Proved Disappointing

Targeted Therapy Proved Disappointing

How far should we go with personalized treatment, or in other words, targeted therapy? Where should we stop? A very important study called SHIVA, published in The Lancet Oncology, answered these questions. This study was also presented at the 2015 ECC Congress held in Vienna last month and attracted all our attention.

As is known, targeted therapies are used in many tumor types. Particularly when treating advanced cancer, we all know that the tumor changes after the treatments we administer. Each change in treatment actually gives the tumor a different biology and characteristic. After a certain period, the patient's general condition and fitness remain good. They expect treatment, but the available treatment options have been exhausted. At this point, two paths lie ahead: we can search for something new, particularly using molecular pathology, and push the boundaries to see whether we can use drugs not established for that individual's tumor. Alternatively, we can enable the patient to live their remaining life with comforting treatment approaches known as best supportive care.

Precisely at this point, with targeted therapies becoming very popular in recent years, the reasoning has emerged that a targeted pathway shown to be effective in one cancer type might also work in treating another. After the planned treatments for a particular cancer type have been completed, identifying all cellular mechanisms known to cause cancer and using an available targeted drug that matches one seems extremely reasonable. However, in science, something that occurs to you and seems logical may not always work. Although this study was negative, it gave us a very important message.

Between 2012-2014, 741 patients were screened against 10 available targeted drugs. The pathways activating the tumor, meaning pathways suitable for targeted treatment, were examined independently of tumor characteristics and the organ of origin. Among 741 patients, 195 had pathways suitable for targeted treatments specific to other cancers, in addition to their own specific targeted pathway. These patients were divided into two groups, with 99 in one and 96 in the other. One group received treatment through the targeted pathway; the other was divided into two arms and received single-agent or dual-agent conventional chemotherapy chosen by the physician, or was monitored without any treatment.

Naturally, with so much progress and popularity in personalized treatments, such a study makes one expect the targeted treatment arm to be very successful. Many patients pay out of pocket for targeted therapies that have been used repeatedly worldwide, with millions of dollars spent in this field. However, the study results showed no significant difference between the two groups. This was highly disappointing. In other words, this study showed that even when we identify an opportunity to use a targeted drug developed for one cancer type against a target in another cancer type, we may not obtain a clear result in practice. Thus, this is an important study showing that oncology and science are not actually easy, and that science cannot be solved through a few practical mathematical solutions or desk-based suggestions.

However, this should not leave us entirely disappointed. Ultimately, the study emphasized the importance of clinical research. Such results must certainly pave the way for clinical research. Patients whose treatment options have been exhausted should receive targeted therapies within a clinical trial protocol. This allows the benefits and harms of treatments to be determined scientifically and provides benefits for the future. Another important point is that this study demonstrates that using scientifically unproven drugs merely because they seem logical to us is inappropriate.

Sources

Le Tourneau C, Delord JP, Gonçalves A.
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Targeted Therapy Proved Disappointing

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy